Empowered by leading technologies as well as a broad range of knowledge in this field, Creative Biolabs has commercialized and launched an innovative and patented CAMouse™ transgenic mouse platform for the discovery of fully human therapeutic antibodies in a natural way.

Impediment in the Development of Therapeutic Antibodies

Since the new era of personalized therapies, the use of monoclonal antibodies (mAb) to treat a broad range of diseases (e.g. cancer, chronic inflammatory diseases, infectious diseases, transplantation, etc.) lies at the heart of this new forefront. However, since the first approval of mAb drugs back in 1986, immunogenicity side effects have always been a major concern that hinders the improvement of most therapeutic antibodies. Multiple strategies have been invented and applied to make antibodies as “human” as possible. Human immunization is definitely not a feasible option due to ethical reasons. Meanwhile, the inherent tolerance of human immune system to human antigens, as well as the fact that human individuals cannot be subjected to common immunization schemes, which greatly limits the accessible antibody repertoire and target range. Humanization approach provides another promising solution, using either framework grafting, phage display, in silico methods. Nevertheless, it is not only time- and cost-consuming, but also with potential risks of compromising the original antibody affinity/specificity.

New Generation of Fully Human Antibody Production

A novel transgenic mouse being capable of producing human antibodies has been emerged in recent years, which is known as an incredibly powerful tool to address these difficulties. This specialty mouse strain is engineered to express human antibody repertoires by introducing human immunoglobin loci (heavy/light chains) into the mouse germlines, while inactivating endogenous mouse Ig genes. Upon immunization, the human Ig transgenes will undergo V(D)J rearrangement, random nucleotide (N region) addition, class switching, and somatic hypermutation to yield diversified antibody pools. This technology has now been exploited by plenty of pharmaceutical and biotechnology companies for therapeutic/diagnostic antibody development, which is now the fastest growing group of mAb drugs in clinical trials.

Two key points for antibody generation through this approach is potent immune response and diversified antibody repertoire. To meet these needs, Creative Biolabs always pursue to provide the optimal humanized transgenic mouse strain with higher efficacy and success rate but lower costs. Now, we are proud to offer the unique and patented CAMouse™ fully human antibody generation platform to researchers all over the world.

Highlight Advantages of CAMouse™ Platform

➢Highly efficient gene introduction: Equipped with world-leading transgenic technology that can introduce gene fragments as long as 800 kb with high precision and efficiency in one time, we guarantee the highest Ig gene KI rate in current market. As is known, large germline repertoire is the prerequisite for generating diverse antibody sequences at 6 CDRs, which is directed correlated with target recognition.

➢100% human sequence: CAMouse™ is able to express fully human antibodies (including the Fc region). This is very important because the chimeric antibodies (although with human V regions) may have potential risks during engrafting human Fc or other framework regions, e.g. losing original binding properties. CAMouse™ fully human antibodies can totally bypass these uncertainties and risks, and thus save lots of valuable time and efforts.

➢Superior immune system performance: For most antibody discovery projects, potent immune response is the key to success. Previous experience suggested that heterologous regulation regions/constant regions can impair B cell development and maturation, leading to weak immune responses. With an exclusive strategy that can achieve potent antibody production as well as fully human sequence, CAMouse™ can amount vigorous immune reactions against a wide range of antigens.

➢Skillful technique team: Creative Biolabs has been focused on antibody discovery and development for more than 10 years. Based on extensive expertise and well-trained technical team, we are devoted to providing custom-tailored, one-stop service to accelerate your antibody discovery pipeline:

➢ Flexible licensing terms: We provide very flexible terms and conditions for out-licensing this amazing tool, making it accessible to all kinds of research and industrial customers. We are open to discuss about this matter.

If you are interested in learning more about the CAMouse™ fully human antibody generation platform or have any special needs in antibody discovery, please do not hesitate to contact us for more details.

Related Sections

Please note: we only produce antibodies for research purposes. Our products and services cannot be used directly on humans.